2006
Therapeutic options to target angiogenesis in human malignancies
Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opinion On Emerging Drugs 2006, 11: 635-650. PMID: 17064223, DOI: 10.1517/14728214.11.4.635.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsHuman malignanciesMonoclonal antibodiesGrowth factorKinase inhibitorsAnti-VEGF inhibitorsGastrointestinal stromal tumorsSolid human malignanciesRenal cell carcinomaBasic fibroblast growth factorRole of VEGFTypes of cancerFibroblast growth factorStromal tumorsTherapeutic optionsCell carcinomaColorectal cancerAntiangiogenic drugsClinical trialsDrug classesPro-angiogenic growth factorsSmall molecule inhibitorsTumor growthTumor angiogenesisMatrix breakdown
2002
Angiogenesis as a target for cancer therapy
Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematology/Oncology Clinics Of North America 2002, 16: 1125-1171. PMID: 12512387, DOI: 10.1016/s0889-8588(02)00047-3.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAngiostatinsAnimalsAntibodies, MonoclonalAnticarcinogenic AgentsCell HypoxiaChildClinical Trials as TopicCollagenCyclooxygenase InhibitorsDrug DesignEndostatinsEndothelium, VascularEphrinsGrowth SubstancesHumansImmunotherapyIntegrin alphaVbeta3LigasesMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMiceNeoplasm ProteinsNeoplasmsNeovascularization, PathologicOutcome Assessment, Health CarePeptide FragmentsPlasminogenProtease InhibitorsReceptors, Eph FamilyReceptors, Growth FactorThrombospondinsTumor Suppressor ProteinsUbiquitin-Protein LigasesVon Hippel-Lindau Tumor Suppressor Protein